Christine Ring - Jan 30, 2024 Form 4 Insider Report for Nurix Therapeutics, Inc. (NRIX)

Role: Chief Legal Officer
Signature: /s/ Daniel Burbach, as Attorney-in-Fact for Christine Ring
Stock symbol: NRIX
Transactions as of: Jan 30, 2024
Transactions value $: -$14,063
Form type: 4
Date filed: 1/30/2024, 06:52 PM
Previous filing: Nov 1, 2023
Next filing: Feb 15, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	NRIX	Common Stock	Options Exercise	$0	+1.92K	+12.61%	$0.00	17.2K	Jan 30, 2024	Direct
transaction	NRIX	Common Stock	Options Exercise	$0	+2K	+11.64%	$0.00	19.2K	Jan 30, 2024	Direct
transaction	NRIX	Common Stock	Sale	-$14.1K	-1.76K	-9.17%	$7.99	17.4K	Jan 30, 2024	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	NRIX	Restricted Stock Units	Options Exercise	$0	-1.92K	-11.11%	$0.00	15.4K	Jan 30, 2024	Common Stock	1.92K	$0.00	Direct	F3, F4, F5
transaction	NRIX	Restricted Stock Units	Options Exercise	$0	-2K	-10%	$0.00	18K	Jan 30, 2024	Common Stock	2K	$0.00	Direct	F5, F6, F7

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
F2	Represents the weighted average sale price. The lowest price at which shares were sold was $7.93 and the highest price at which shares were sold was $8.06. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.
F3	Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.
F4	The RSUs will vest in substantially equal increments quarterly over four years, with the first quarterly increment vesting on April 30, 2022, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's Common Stock will be delivered to the Reporting Person following vesting.
F5	RSUs do not expire; they either vest or are canceled prior to the vest date.
F6	Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock upon settlement.
F7	The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2023, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting.